Ignite Creation Date:
2025-12-26 @ 12:14 PM
Ignite Modification Date:
2026-03-08 @ 3:57 AM
Study NCT ID:
NCT03914300
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-14
First Post:
2019-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Differentiated Thyroid Gland Carcinoma | View |
| None | Follicular Variant Thyroid Gland Papillary Carcinoma | View |
| None | Poorly Differentiated Thyroid Gland Carcinoma | View |
| None | Refractory Differentiated Thyroid Gland Carcinoma | View |
| None | Refractory Thyroid Gland Carcinoma | View |
| None | Tall Cell Variant Thyroid Gland Papillary Carcinoma | View |
| None | Thyroid Gland Follicular Carcinoma | View |
| None | Thyroid Gland Oncocytic Carcinoma | View |
| None | Thyroid Gland Papillary Carcinoma | View |
Keywords: